Refractory/relapse thrombocytopenia in a patient with Evans’ syndrome successfully treated with zanubrutinib

Abstract excerpt

<h4>Background: </h4> Evans’ syndrome (ES) is a rare autoimmune disorder and has high mortality rate. Due to the rarity of the disease, the treatments of ES are always emprical, including steroids, IVIG, rituximab, TPO-RAs, immunosuppressants, splenectomy and supportive therapies. However, many patients may become relapsed/refractory to a series of different interventions. Herein, we report a case that a ES patien...

Topics

Open a Topic to create a Post that cites this publication.

• Agammaglobulinaemia Tyrosine Kinase
• Autoimmune Diseases
• Chronic Lymphocytic Leukemia Research
• Disease Progression
• Mutation
• Protein Kinase Inhibitors
• Pyrimidines
• Receptors, Antigen, B-Cell

Identifiers and source

Literature Corpus work

6c145cf2-f7b4-52f0-b76d-32949f326e9b

DOI

10.21203/rs.3.rs-1540326/v2